MGMT Methylation Analysis Kit
£1,474.00
The geneMAP™ MGMT Methylation Analysis Kit is a cutting-edge tool designed for the detection and quantitative analysis of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation in genomic DNA from glioblastoma multiforme (GBM) tumors. Utilizing methylation-specific real-time PCR (MSP) technology, this CE-IVD certified kit offers superior analytical sensitivity and specificity and is compatible with FAM and VIC/HEX two-color real-time PCR instruments. MGMT promoter methylation is a key biomarker for increased sensitivity to alkylating agents like temozolomide, making it crucial for therapeutic decision-making and prognosis in GBM treatment.
The geneMAP™ MGMT Methylation Analysis Kit is a cutting-edge tool designed for the detection and quantitative analysis of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation in genomic DNA from glioblastoma multiforme (GBM) tumors. Utilizing methylation-specific real-time PCR (MSP) technology, this CE-IVD certified kit offers superior analytical sensitivity and specificity and is compatible with FAM and VIC/HEX two-color real-time PCR instruments. MGMT promoter methylation is a key biomarker for increased sensitivity to alkylating agents like temozolomide, making it crucial for therapeutic decision-making and prognosis in GBM treatment.
- Methylation-Specific PCR: Enhances sensitivity and specificity in detecting MGMT promoter methylation.
- Multiplex Real-time PCR Technology: Enables fast, efficient, and quantitative analysis of methylation levels.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX two-color real-time PCR instruments, broadening its applicability.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, affirming its reliability and quality.
- Accurate Quantification of Methylation Levels: Provides precise methylation percentages, offering valuable insights into the methylation status of the MGMT promoter.
- Guides Treatment Decisions: The detection of MGMT promoter methylation can inform clinicians about the likely efficacy of temozolomide treatment, aiding in personalized therapy plans.
- Rapid and User-Friendly: Streamlines the testing process, allowing for quick and efficient assessment of methylation status.
- Prognostic and Therapeutic Decision-Making in GBM: Essential for assessing MGMT promoter methylation status, which is linked to better responses to alkylating agents and favorable prognosis in glioblastoma multiforme patients.
- Technology: Utilizes methylation-specific and multiplex real-time PCR for precise detection and quantification of MGMT promoter hypermethylation.
- Compatibility: Suitable for FAM and VIC/HEX two-color real-time PCR instruments.
- Methylation Analysis: Offers quantitative methylation analysis, calculating the methylation level percentage.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
